Position in EXEL
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$1,671,529
+$418,498 QoQ
Shares Held
30,721
+5.2% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#284
of 756 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 25%
Shared 0%
None 75%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Pallas Capital Advisors LLC holds $30,351,010 across 36 Biotechnology names. EXEL ranks #4 (5.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
40,511 | $9,915,877 | |
| 2 | RPRX |
Royalty Pharma plc
|
108,585 | $6,088,360 | |
| 3 | INCY |
Incyte Corp
|
32,151 | $3,644,637 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
30,721 | $1,671,529 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,920 | $1,197,196 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,200 | $1,092,806 | |
| 7 | FTRE |
Fortrea Holdings Inc.
|
39,499 | $687,282 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,203 | $663,169 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,671,529 | 30,721 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $1,253,031 | 29,215 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $2,115,411 | 48,264 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $1,398,376 | 33,859 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $1,975,489 | 44,816 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $1,759,201 | 47,649 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $743,489 | 22,327 | Shares | Sole | 2025-01-13 | |
| 2024-09-30 | $227,192 | 8,755 | Shares | Sole | 2024-10-25 | |
| No filing history on record for this holder in this stock. | ||||||